130 related articles for article (PubMed ID: 8877491)
1. An experimental study on the neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia.
La Noce A; Miragoli L; Samuelli G; Tirone P
Invest Radiol; 1996 Sep; 31(9):550-5. PubMed ID: 8877491
[TBL] [Abstract][Full Text] [Related]
2. Neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia: EEG evaluation.
La Noce A; Frigeni V; Demicheli F; Miragoli L; Tirone P
Invest Radiol; 1999 Apr; 34(4):262-7. PubMed ID: 10196717
[TBL] [Abstract][Full Text] [Related]
3. Neurotolerability of gadobenate dimeglumine. Evaluation of brain dopamine concentration in freely moving rats by microdialysis.
La Noce A; Frigeni V; Filatori I; Danieli A; Tirone P
Invest Radiol; 1999 Aug; 34(8):543-7. PubMed ID: 10434187
[TBL] [Abstract][Full Text] [Related]
4. Neurotolerability of contrast agents in rats with brain ischemia induced by transient middle cerebral artery occlusion: EEG evaluation.
Frigeni V; Miragoli L; Grotti A; Lorusso V
Invest Radiol; 2001 Jan; 36(1):1-8. PubMed ID: 11176255
[TBL] [Abstract][Full Text] [Related]
5. Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials.
Frigeni V; Miragoli L; Grotti And A; Lorusso V
Invest Radiol; 2001 Oct; 36(10):561-72. PubMed ID: 11577266
[TBL] [Abstract][Full Text] [Related]
6. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart.
Akre BT; Dunkel JA; Hustvedt SO; Refsum H
Acad Radiol; 1997 Apr; 4(4):283-91. PubMed ID: 9110026
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats.
Ray DE; Cavanagh JB; Nolan CC; Williams SC
AJNR Am J Neuroradiol; 1996 Feb; 17(2):365-73. PubMed ID: 8938312
[TBL] [Abstract][Full Text] [Related]
8. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: toxicity and MR findings.
Roman-Goldstein SM; Barnett PA; McCormick CI; Szumowski J; Shannon EM; Ramsey FL; Mass M; Neuwelt EA
J Comput Assist Tomogr; 1994; 18(5):731-6. PubMed ID: 8089321
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.
Cavagna FM; Maggioni F; Castelli PM; Daprà M; Imperatori LG; Lorusso V; Jenkins BG
Invest Radiol; 1997 Dec; 32(12):780-96. PubMed ID: 9406019
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cardiovascular changes after administration of gadodiamide injection and gadopentetate dimeglumine in dogs.
Bøkenes J; Hustvedt SO; Refsum H
Acad Radiol; 1997 Mar; 4(3):204-9. PubMed ID: 9084778
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.
Heinrich MC; Kuhlmann MK; Kohlbacher S; Scheer M; Grgic A; Heckmann MB; Uder M
Radiology; 2007 Feb; 242(2):425-34. PubMed ID: 17179401
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
Cheong BY; Duran C; Preventza OA; Muthupillai R
AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
[TBL] [Abstract][Full Text] [Related]
13. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
14. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.
Morisetti A; Bussi S; Tirone P; de Haën C
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S207-17. PubMed ID: 10608416
[TBL] [Abstract][Full Text] [Related]
15. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium.
Berthezène Y; Mühler A; Lang P; Shames DM; Clément O; Rosenau W; Kuwatsuru R; Brasch RC
J Magn Reson Imaging; 1993; 3(1):125-30. PubMed ID: 8428078
[TBL] [Abstract][Full Text] [Related]
16. [Mutagenicity study of gadobenate dimeglumine formulation (E7155) (3)--Micronucleus test in rat bone marrow cells].
Toritsuka N; Daimon H; Sawada S; Sagami F; Tirone P; Morisetti A; Bussi S; Fassio F
J Toxicol Sci; 1999 Nov; 24 Suppl 1():103-6. PubMed ID: 10637785
[TBL] [Abstract][Full Text] [Related]
17. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
18. General pharmacology in experimental animals of gadobenate dimeglumine (MultiHance), a new magnetic resonance imaging contrast agent.
Tirone P; Castano M; Cipolla P; Frigeni V; La Noce A; Luzzani F; Valenti R; de Haën C
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S195-206. PubMed ID: 10608415
[TBL] [Abstract][Full Text] [Related]
19. Gadobenate dimeglumine and cerebral glucose metabolism. Continuous monitoring of striatal lactate levels in freely moving rats.
La Noce A; Frigeni V; Filatori I; Danieli A; Tirone P
Acta Radiol; 2000 Jul; 41(4):394-9. PubMed ID: 10937766
[TBL] [Abstract][Full Text] [Related]
20. Early MR detection of experimentally induced cerebral ischemia using magnetic susceptibility contrast agents: comparison between gadopentetate dimeglumine and iron oxide particles.
Reith W; Forsting M; Vogler H; Heiland S; Sartor K
AJNR Am J Neuroradiol; 1995 Jan; 16(1):53-60. PubMed ID: 7900602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
